Nogapendekin alfa inbakicept
- Generic Name
- Nogapendekin alfa inbakicept
2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT)
- Conditions
- Multiple Myeloma
- Interventions
- Procedure: Autologous Stem Cell Transplant (ASCT)Biological: Expanded Natural Killer (ENK) Cells
- First Posted Date
- 2016-12-28
- Last Posted Date
- 2020-07-10
- Lead Sponsor
- University of Arkansas
- Registration Number
- NCT03003728
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Relapse Prophylaxis With N-803 for AML and MDS Pts Following Allo HSCT
- Conditions
- Acute Myelogenous Leukemia (AML)Myelodysplastic Syndrome (MDS)
- Interventions
- First Posted Date
- 2016-12-12
- Last Posted Date
- 2023-11-03
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 20
- Registration Number
- NCT02989844
- Locations
- 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Procedure: LeukapheresisProcedure: Graft cell infusionProcedure: CIML NK cell infusion
- First Posted Date
- 2016-05-25
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 60
- Registration Number
- NCT02782546
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Proof of Principle Study of Pulse Dosing of IL-15 to Deplete the Reservoir in HIV Infected People
- First Posted Date
- 2014-07-16
- Last Posted Date
- 2020-01-27
- Lead Sponsor
- University of Minnesota
- Target Recruit Count
- 10
- Registration Number
- NCT02191098
- Locations
- 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
QUILT-3.005: A Study of ALT-803 in Patients With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2014-03-31
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Altor BioScience
- Target Recruit Count
- 18
- Registration Number
- NCT02099539
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors
- First Posted Date
- 2013-09-20
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Altor BioScience
- Target Recruit Count
- 26
- Registration Number
- NCT01946789
- Locations
- 🇺🇸
Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States
🇺🇸Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸University of Washington, Seattle Cancer Care Alliance, Seattle, Washington, United States
Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- Procedure: LeukapheresisBiological: Cytokine-induced killer cellsBiological: IL-2Procedure: Peripheral blood for correlative studiesProcedure: Bone marrow for correlative studies
- First Posted Date
- 2013-07-12
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 89
- Registration Number
- NCT01898793
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.